These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 34154614)

  • 1. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
    Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
    J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.
    Chen M; Jiang M; Wang X; Shen L; Li J
    Expert Opin Biol Ther; 2022 Oct; 22(10):1227-1232. PubMed ID: 36124972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Harb W; Peer CJ; Hua Q; Xu S; Lu H; Lu N; He Y; Xu T; Dong R; Gong J; Liu D
    Oncologist; 2021 Sep; 26(9):e1514-e1525. PubMed ID: 33973293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis.
    Fan S; Gai C; Li B; Wang G
    Oncol Lett; 2023 Aug; 26(2):351. PubMed ID: 37545619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
    J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
    Le DT; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Atreya CE; Cui Y; Dai T; Marinello P; Diaz LA; André T
    J Clin Oncol; 2020 Jan; 38(1):11-19. PubMed ID: 31725351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial.
    Chen J; Quan M; Chen Z; Zeng T; Li Y; Zhou Y; Hai Y; Gao Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2651-2657. PubMed ID: 32623573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
    Shimizu T; Nakajima TE; Yamamoto N; Yonemori K; Koyama T; Kondo S; Sunakawa Y; Izawa N; Horie Y; Xiang S; Xu S; Qin L; Gong J; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1021-1031. PubMed ID: 35932387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
    Yu JH; Xiao BY; Li DD; Jiang W; Ding Y; Wu XJ; Zhang RX; Lin JZ; Wang W; Han K; Kong LH; Zhang XK; Chen BY; Mei WJ; Pan ZZ; Tang JH; Zhang XS; Ding PR
    Lancet Oncol; 2024 Jul; 25(7):843-852. PubMed ID: 38852601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer.
    Li Y; Zhang W; Du J; Hu J; Hu R; Zeng Z; Jin-Si-Han EE; Lian S; Wang H; Li Y; Pan Z; Feng C; Zhang X; Lu Z
    Target Oncol; 2024 Jul; 19(4):601-610. PubMed ID: 38691294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
    Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
    Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: Envafolimab causes local skin necrosis.
    Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
    Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
    Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
    Berton D; Pautier P; Lorusso D; Gennigens C; Gladieff L; Kryzhanivska A; Bowman J; Tian C; Cornfeld M; Van Gorp T
    Gynecol Oncol; 2024 Jul; 186():191-198. PubMed ID: 38824752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Envafolimab: First Approval.
    Markham A
    Drugs; 2022 Feb; 82(2):235-240. PubMed ID: 35122636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.